Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vebreltinib + temozolomide
- Development stage
- Unknown
- Lead developer
- Apollomics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Vebreltinib + temozolomide is an investigational combination therapy being studied for the treatment of glioblastoma, particularly in patients with IDH-mutant or secondary glioblastoma harboring PTPRZ1-MET fusion gene positivity. Vebreltinib (also known as PLB1001 or APL-101) is a small molecule inhibitor targeting the MET proto-oncogene receptor tyrosine kinase (MET), which plays a role in tumor growth and survival. Temozolomide is an oral alkylating agent that induces DNA damage leading to apoptosis in cancer cells. The combination aims to leverage targeted inhibition of MET-driven signaling alongside cytotoxic chemotherapy to improve outcomes in aggressive brain tumors[1][2][3][7].
- Other names
- bozitinib + temozolomide
02
Targets
DNAMET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on vebreltinib + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vebreltinib + temozolomide.